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Edited by Lukas HuberAbstract Small interfering RNAs have evolved as eﬀective tools
for the study of gene functions. Here, we demonstrate the use of
diﬀerent siRNAs for the speciﬁc knock down of the STAT6 tran-
scription regulator and the complete silencing of the downstream
signaling pathway. The knock down of STAT6 resulted in a com-
plete loss of STAT6 speciﬁc DNA binding activity and blocked
the release of eotaxin-3 in human epithelial cells (BEAS-2B)
stimulated with IL-4 and TNFa with no signs of unspeciﬁc gene
silencing. Other signaling pathways like the EGF stimulated re-
lease of IL-8 were still active in BEAS-2B cells treated with
STAT6 speciﬁc siRNAs, demonstrating the speciﬁcity of these
molecules.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: RNA interference; siRNA; STAT6; IL-4; Eotaxin;
Asthma1. Introduction
Asthma, an increasingly common disease characterized by
airway obstruction and bronchial hyper-responsiveness
(BHR), is caused by acute and chronic bronchial inﬂamma-
tion. The molecular and cellular mechanisms mediating the
allergic inﬂammatory cascade involve multiple mediators, cell
types and pathways. T helper type 2 (Th2) cytokines like IL-
4 and IL-13 are believed to play a central role in the initiation
and the progression of this disease [1]. For example, IL-4 is
essential for the commitment of naı¨ve CD4+ T-cells into the
Th2-phenotype and Th2 cell proliferation, whereas IL-13 is
known to aﬀect BHR. In addition, IL-4 and IL-13 share sev-
eral biological responses due to a common signaling pathway.
Both cytokines promote eosinophilic inﬂammation through
induction of eotaxin production in bronchial epithelial cells
and ﬁbroblasts [2]. IL-4 and IL-13 also increase airway mucus
secretion and both are required for the induction of the IgE
isotype switch.
The key event for IL-4 and IL-13 mediated biological eﬀects
is the activation of the signal transducer and activator of tran-
scription 6 (STAT6) [3]. STAT6 belongs to a family of tran-*Corresponding author. Fax: +41 7351 545155.
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(S. Hobbie).
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doi:10.1016/j.febslet.2004.11.071scription regulators that mediate signal transduction upon
binding to phosphorylated receptors via a SH2 domain.
Phosphorylation by receptor bound JAK-kinases is then fol-
lowed by a SH2 domain dependent homo- or hetero-dimer for-
mation in the cytoplasm. Subsequent translocation into the
nucleus causes recognition of STAT6 speciﬁc DNA-binding
elements and enhanced transcription of target genes. The
JAK/STAT signaling pathways are stringently controlled and
a negative feedback control is the competition of the silencers
of cytokine signaling (SOCS) with STATs for the JAK-kinase
activation mechanism [4]. Especially for the STAT6 signaling,
a silencing through the IFNc/STAT1 pathway via the induc-
tion of SOCS1 gene expression was demonstrated in diﬀerent
cell lines [5–7].
The main eﬀects triggered by IL-4 and IL-13 are reduced or
eliminated in allergen provocation experiments in STAT6/
mice [8], implying that the inhibition of STAT6-mediated tran-
scription might reduce the IL-4 and IL-13 associated features
of human asthma.
Small molecule drugs able to interfere with the functional
domains of STAT6 (e.g., the DNA-binding domain or the
SH2 domain) have not been identiﬁed so far. Therefore ‘‘bio-
logical therapies’’ emerge as potential alternatives to target this
important pathway. One of the most promising technologies
takes advantage of the intracellular recognition of double
stranded RNA for the posttranscriptional silencing of gene
expression [9]. This RNA interference (RNAi) was ﬁrst de-
scribed in plants but the principal mechanism has also been
demonstrated in worms, ﬂies and mammalian cells [10,11].
Double stranded RNA is cleaved by Dicer, a RNAse III nucle-
ase family member, and processed into 21–28 nucleotide small
interfering RNAs (siRNAs) [12]. These double stranded oligo-
nucleotides are incorporated into a RNA-induced silencing
complex (RISC), which cleaves the target mRNA sequence.
Speciﬁcity of the silencing is very high and even single mis-
matches are weakly tolerated [13]. However, in mammalian
cells, unspeciﬁc eﬀects have been described once the siRNA
concentration is high enough to activate a general silencing
of gene expression by the interferon pathway, indicated by a
ﬁve to tenfold upregulation of STAT1 [14]. In addition, spe-
ciﬁc binding of the siRNA to homologous sequences [15] or
low stringency binding to 3 0 regions of unrelated messages
[16] can lead to posttranscriptional repression or, respectively,
the blockage of translation of other target sequences.
In view of the central role of the transcription factor STAT6
in asthma, the eﬃcacy of diﬀerent STAT6 siRNA-oligonucle-
otides to downregulate the STAT6 protein was investigated.
Eﬀective STAT6 siRNAs were able to block IL-4 dependentblished by Elsevier B.V. All rights reserved.
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line. Furthermore, no unspeciﬁc eﬀects of STAT6 siRNAs on
STAT6 independent pathways were seen. Taken together,
these data suggest that STAT6 siRNAs might have a therapeu-
tic potential.2. Materials and methods
2.1. siRNA preparation
Single stranded RNA-oligonucleotides were synthesized and 2 0-OH
deprotected at Dharmacon, Inc. (Lafayette, USA). Annealing of com-
plementary oligonucleotides according to the manufacturers instruc-
tions was controlled on 4% NuSieve low melting agarose gels. The
design of the siRNAs followed mainly the rules of Tuschl [17]. The
number coding of the siRNAs resembles the position of the siRNA se-
quence within the EMBL U16031.1 STAT6 sequence version. The
sense sequences of the siRNAs were 5 0-CAGUUCCGCCACUUG-
CCAAdTdT-3 0 (si502), 5 0-AGCCUGGUGGACAUUUAUUdTdT-
3 0 (si853), 5 0-GAUGUGUGAAACUCUGAACdTdT-3 0 (si1515),
5 0-CAGAUGGGUAAGGAUGGCAdTdT-3 0 (si2062). Control
experiments were performed with siRNA speciﬁc for lacZ. After
5 0-FITC labeling of the sense strand (5 0-FITCUGGCGAUUAC-
CGUUGAUGUdTdT-30), this control was used in addition for the
evaluation of transfection eﬃciencies.2.2. Cell culture, siRNA transfection and cytokine stimulation
Human cell lines were exponentially grown under standard condi-
tions. The growth media were RPMI 1640 (Gibco) supplemented with
Glutamax (Invitrogen) for Jurkat, DMEM (Invitrogen) for HEK293
and HamsF12 (Cambrex) for BEAS-2B cells. Media were supple-
mented with 10% FCS (Hyclone). For transfection experiments,
4 · 105 cells per well were seeded in a 6-well plate and incubated over-
night in normal growth medium to reach 50–70% conﬂuency. Cells
were transfected with 100 nM siRNA in the presence of 10 ll Lipofec-
tamine 2000 (Invitrogen) in 2 ml of normal growth medium. Transfec-
tion eﬃciency was controlled 4 h after the addition of FITC labeled
siRNA under a ﬂuorescence microscope. 32 h post transfection, the
cells were stimulated for 16 h by addition of fresh growth medium, sup-
plemented with human TNFa (100 ng/ml), human IL-4 (50 ng/ml) or
human EGF (50 ng/ml). The conditioned medium was stored at 20
C for further analysis of the cytokine content and the cells were har-
vested by the addition of lysis reagents.2.3. RNA isolation and qRT-PCR
Cells were lysed by the addition of 700 ll per well of RLT buﬀer and
the total RNA was isolated from the lysate according to the RNeasy
protocol (Qiagen). Brieﬂy, genomic DNA was sheared by centrifuga-
tion of the lysate through qiashreddere spin columns (10 000 · g, 2
min, Qiagen) and the RNA was precipitated by the addition of 1
vol. of 70% ethanol. The precipitate was applied on RNeasy spin col-
umn (Qiagen), DNAse treated and eluted in 60 ll DEPC-H2 O accord-
ing to the manufacturers protocol.
The gene expression levels were determined by TaqMan analysis in a
7900HT Sequence Detection System (Applied Biosystems) using Taq-
Man EZ RT-PCR reagent kit (Applied Biosystems) for the reverse
transcription and PCR ampliﬁcation in ABI PRISM 384 well optical
reaction plate (Applied Biosystems). Gene speciﬁc probe was labeled
with 6-FAMe and TAMRA for internal quenching. Primers- and
Mn+2-concentrations were optimized to reach 100% ampliﬁcation eﬃ-
ciency according to the manufacturers instructions. For the normali-
zation of TaqMan, GAPDH control reagents were used (Human)
(JOEe Probe, Applied Biosystems). The gene speciﬁc forward-,
reverse- and probe primer sequences were 5 0-CCTTTTGGC
AGTGGTTTGATG-3 0, 5 0-GTTTGCTGATGAAGCCAATGATC-
3 0, 5 0-CCTCACCAAACGCTGTCTCCGGA-3 0 for STAT6 and
5 0-GTGCCAGCCTGGTTTGGT-30, 5 0-AGCTGGCTGACGTTGG-
AGAT-30, 5 0-AGACGACCTCTCTGCCCGTTGTGG-3 0 for STAT1.
The SOCS1 gene expression was analyzed by the human SOCS1
speciﬁc TaqMan gene expression assay (Hs00705164_s1, Applied
Biosystems).2.4. Western blot analysis
Cell lysates (5 · 105 cells/lane) were separated by SDS–PAGE and
transferred to Immobilon-P Transfer Membrane (Milipore, Bedford,
MA, USA). Blots were blocked in 1· TBS/5% milk-powder overnight
and incubated with anti-STAT6 (sc-621; 10 lg/ml; Santa Cruz Biotech-
nology, Santa Cruz, USA) or anti-STAT1 (sc-346; 10 g/ml; Santa Cruz
Biotechnology, Santa Cruz, USA), washed three times with 1· TBS/
0.1% Tween20 and incubated with HRP-conjugated secondary anti-
body. For the analysis of diﬀerent protein levels on the same blot,
membranes were stripped with ReBlote Western blot recycling kit
(Chemicon). Immunoreactive bands were visualized using ECL (Amer-
sham Biosciences Europe GmbH, Roosendaal, Netherlands).
2.5. Cytokine ELISAs
Concentrations of eotaxin-3 (CCL26) and IL-8 (CXCL8) in the cell
supernatant were determined with human eotaxin-3 Quantikine (R&D
systems, DCC260) and with OptEIA human IL-8 Set (BD/Pharmin-
gen, # 555244).
2.6. Electrophoretic mobility shift assay
BEAS-2B cells were pelleted by centrifugation at 1000 · g, washed
once in PBS and lysed in lysis buﬀer (20 mM HEPES pH 7.4, 100
mM NaCl, 50 mM NaF, 1 mM DTT, and 10% glycerol) by freeze–
thawing. After three freeze and thaw cycles (RT, liquid N2), the lysate
was centrifuged at 10 000 · g for 5 min at 4 C and the supernatant was
used after the quantiﬁcation of protein concentration for the EMSA. 5
lg protein was reconstituted in Band Shift Buﬀer (10 mM Tris HCl,
pH 7.5, 50 mM NaCl, 1 mM DTT, 1 mM EDTA, 0.5 mg/ml BSA,
0.2 lg/ml pdIdC, and 5% glycerol) and incubated with 50 fmol DNA
probe end-labeled with [a-32P] ATP for 15 min at 4 C. STAT6 probe:
5 0-AGATTAAAGTTCCTGTGAAGGTCTT-3 0 (STAT6 binding se-
quence out of the IL-4 promoter), STAT1 probe: 5 0-AGCTT-
CATTTCCCGTAAATCCCTA-3 0. Samples were separated by
electrophoresis on 4% polyacrylamide gels in 0.5% TBE (Tris-borate
EDTA) and bands were visualized by autoradiography.3. Results
3.1. Identiﬁcation of STAT6 speciﬁc siRNA
The knock down eﬃciencies of the STAT6 siRNA molecules
were ﬁrst analyzed in HEK293 cells due to the high transfec-
tion eﬃciencies achievable in this cell line. The knock down
eﬃciencies after transient transfection of the siRNAs were ana-
lyzed by STAT6 speciﬁc qRT-PCR. Transfections without siR-
NA or with the lacZ speciﬁc siRNA served as a control for
transfection reagent and double stranded RNA induced gen-
eral silencing of transcription. Transfection eﬃciency was ana-
lyzed 4 h after transfection by ﬂuorescence imaging and more
than 90% of the cells were stained positive by an intracellular
speckled pattern of the FITC-labeled oligonucleotides. As
shown in Fig. 1, the remaining STAT6 mRNA levels 48 h after
the transfection were 16 ± 4% for si502, 35 ± 16% for si853,
26 ± 10% for si1515 and 36 ± 17% for si2062, compared to
control [no siRNA, control].3.2. Knock down of STAT6 in BEAS-2B cells and blockage of
IL-4 signaling
As a next step, the functional eﬀects of a STAT6 knock
down were analyzed in the human bronchial epithelial cell line
BEAS-2B in which the STAT6 pathway has been described in
detail [18]. Cells transfected with the two most eﬀective siR-
NAs, si502 and si1515, or with the lacZ speciﬁc siRNA as con-
trol were stimulated with TNFa and IL-4 in order to increase
the STAT6 gene expression and to activate the STAT6 signal-
ing pathway. The eﬀects of the treatments were ﬁrst analyzed
on the mRNA level by qRT-PCR (Fig. 2). The cytokine stim-
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Fig. 1. Identiﬁcation of potent STAT6 siRNAs: HEK293 cells were transfected with siRNAs speciﬁc for STAT6, lacZ or mock transfected. After 48
h, the cells were lysed and the knock down eﬃciencies of the siRNAs were analyzed by qRT-PCR and normalized for the GAPDH expression levels.
The STAT6 expression level of the mock transfected cells was set as 100%. Results represent the mean of triplicate experiments including standard
deviations (S.D.).
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Fig. 2. Gene expression of STAT6, STAT1 and the target gene SOCS1: SOCS1 gene expression follows the reduction of STAT6 expression level and
is not induced by the upregulation of STAT1. BEAS-2B cells were transfected with siRNAs and stimulated after 32 h with IL-4 and TNFa for 16 h.
STAT6, STAT1 and SOCS1 mRNA levels were determined by qRT-PCR from cell extracts. Mock transfected cells were set as 100% and results
represent means of six (except unstimulated siLacZ n = 4) experiments, including standard deviations (S.D.).
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siRNA] to 100% [no siRNA, control] in the level of STAT6
mRNA. Treatment of the cells with the lacZ speciﬁc siRNA
had marginal inﬂuence on this cytokine stimulated regulation.
In the presence of STAT6 speciﬁc siRNA molecules, si502 and
si1515, the mRNA levels of STAT6 were reduced in the cyto-
kine stimulated cells to 31% [si502] or 39% [si1515] of the con-
trol cells [no siRNA, control]. In unstimulated cells, the
STAT6 mRNA levels were also reduced to 36% [si502] and
31% [si1515] compared to the same control of cytokine stimu-
lated cells [no siRNA, control].
The STAT1 gene expression in these samples showed a con-
sistent upregulation upon siRNA treatment regardless of the
siRNA sequence. The maximum fold changes were 2.3-fold
for siLacZ in the unstimulated cells (60% [no siRNA] versus
139% [siLacZ]) and 1.8-fold for si502 in the cytokine stimu-
lated cells (100% [no siRNA, control] versus 179% [ si502]).
The SOCS1 gene expression was used as a marker for JAK/
STAT signaling. The regulation of SOCS1 gene expression fol-
lowed the STAT6 expression levels: only background expres-
sion levels were seen in all unstimulated cells. Upon Il-4/TNFa stimulation, the expression level increased 10-fold in
control and siLacZ treated cells. Knock down of STAT6 in
cytokine stimulated cells resulted in 62% [si502] or 39%
[si1515] of SOCS1 gene expression compared to control treated
cells [no siRNA, control].
Western blot analysis of total cell lysates (Fig. 3) demon-
strates a strong reduction of STAT6 protein in the siRNA trea-
ted samples compared to the control samples regardless of the
absence or presence of the cytokine stimulation. This protein
knock down was more pronounced for the si502 compared
to the si11515 siRNA. Speciﬁcity of the RNAi activity on pro-
tein levels was assessed by the STAT1 speciﬁc Western blot,
which showed unchanged protein levels regardless of cytokine
stimulation or siRNA treatment.
To address whether the reduced STAT6 protein levels would
result in the silencing of the STAT6 signal cascade, an in vitro
DNA binding assay was performed (Fig. 4). Speciﬁc binding of
STAT6 to the IL-4 promoter region was observed after cyto-
kine stimulation (lanes 1 and 3) and was undetectable in the
siRNA treated samples (lanes 5 and 7). As a control for spec-
iﬁcity, the signals could be super-shifted by incubation of the
Fig. 3. Reduction of STAT6 protein by STAT6 speciﬁc siRNAs: BEAS-2B cells were transfected with siRNAs speciﬁc for STAT6, lacZ or mock
transfected. After 32 h, the cells were stimulated with IL-4 and TNF for 16 h prior to cell lysis. Western blot was analyzed by speciﬁc antibodies for
STAT6 or, after stripping of the STAT6 signal, for STAT1 as indicated. STAT6 Western blot signals of unknown protein served as loading control
(marked with asterisk).
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vation of STAT1 was observed using a STAT1-speciﬁc DNA
probe (Fig. 4).
3.3. Speciﬁcity control of STAT6 knock down on the EGF
signaling pathway
In a ﬁnal set of experiments, it was addressed whether the
siRNAs would speciﬁcally interfere with STAT6 mediated sig-
nal transduction or impact unrelated signaling pathways. In
BEAS-2B cells, EGF leads to AP-1 and NF-jB dependent
secretion of IL-8. As a cellular readout, the eotaxin-3 release
from BEAS-2B cells stimulated with IL-4 and TNFa and the
costimulation with EGF for the release of IL-8 was chosen.
As shown in Fig. 5, the eotaxin-3 concentrations in the culture
supernatant were at background levels (3%) in unstimulated
cells and increased about 33-fold after stimulation of the cells
with IL-4 and TNFa. Treatment of the cells with STAT6 spe-Fig. 4. Reduction of STAT6 expression by speciﬁc siRNAs abrogates the DN
with IL-4 and TNFa after transient siRNA transfection. Cell lysates were
separated by 4% PAGE. Binding of activated STAT6 is leading to reduced
positive control for STAT1 DNA binding activity, the band shift of STA
stimulated Jurkat cells is shown (lanes 17 and 18). As a control for speciﬁcity,
of speciﬁc antibodies (lanes marked with an asterisk).ciﬁc siRNAs prior to the cytokine stimulation resulted in a ten-
fold decreased response of eotaxin-3 secretion (13% [si502] and
10% [si1515] compared to 100% [no siRNA, control]). As
shown by the IL-8 secretion, BEAS-2B cells were fully compe-
tent for the AP-1 and NF-jB dependent signaling. Treatment
of the cells with EGF resulted in a tenfold increased secretion
of IL-8 into the supernatant regardless of the siRNA treatment
and the pronounced reduction of the eotaxin-3 secretion.4. Discussion
The data presented demonstrate that we identiﬁed two selec-
tive STAT6 siRNA molecules which were able to reduce
STAT6 mRNA and protein levels in diﬀerent cell lines. The
depletion of STAT6 resulted in a loss of IL-4 and TNFa med-
iated stimulation of the eotaxin-3 release. Although we foundA binding of activated STAT6: BEAS-2B cells were stimulated for 16 h
incubated with labeled STAT6 or STAT1 speciﬁc DNA probes and
electrophoretic mobility as indicated by the arrow (lanes 1 and 3). As
T1 speciﬁc DNA probes incubated with lysates of IFNc (100 U/ml)
binding of the probe to STAT6 or STAT1 was blocked in the presence
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Fig. 5. EGF-mediated activation of IL-8 secretion is not blocked by STAT6 speciﬁc siRNAs: BEAS-2B cells were transfected as described and
stimulated with IL-4, TNFa and EGF for 16 h. The supernatants were analyzed by ELISAs for the content of eotaxin-3 and IL-8. Results represent
means of triplicate experiments, including standard deviations (S.D.).
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concentration of the siRNAs used in our assays, the expression
had no impact on protein levels or DNA binding activity of
STAT1. The negative crosstalk of the STAT6 and the STAT1
pathways was further excluded by the analysis of the SOCS1
gene expression. Upregulation of SOCS1 was only found in
IL-4/TNFa stimulated cells without indication of an IFNc
mediated regulation in the presence of siRNAs. Therefore,
we conclude that the STAT6 silencing was highly speciﬁc leav-
ing related pathways untouched. The value of these siRNA
molecules can be estimated from the high demand of alterna-
tives to the corticosteroids actually used as standard asthma
therapeutics and the lack of small molecule therapeutics able
to interfere with this inﬂammation pathway. The further use
of the RNAi technology will be highly dependent on the appli-
cation route for in vivo experiments and therapeutic treatment.
In this study, we complexed the RNA-oligonucleotides to en-
able the uptake into adherent cell cultures. Despite the fact
that TNFa speciﬁc siRNAs complexed with DOTAP were
used to prevent LPS induced sepsis in mouse peritoneum
[19], the therapeutic use of this method is limited. Recently,
the application of uncomplexed oligonucleotides became feasi-
ble by the injection of large volumes into the tail vein of mice
[20,21] mainly aﬀecting the expression of liver genes. More-
over, Zhang et al. [22] used the intranasal administration to de-
liver siRNAs to the mouse airway epithelium and parenchyma.
These data suggest that a direct application of siRNAs into the
lung might be feasible.
The STAT6 siRNAs described here may oﬀer a novel ap-
proach to block STAT6 pathways in the airway epithelium
after delivery to the lung. The blockage of STAT6 should lead
to a reduced mucus production accompanied by a decreased
eosinophilia and low 15-lipoxygenase activity [23,24]. Eﬀects
on underlying cell layers are expected for the remodeling of
extracellular matrix (ECM) and airway hyper-responsiveness
due to a decreased IL-13 signaling [25]. Reduced STAT6
expression in the blood system should interfere with Th2 diﬀer-
entiation, IgE switch, B-cell proliferation and mast cell activity
[26–29]. Up to now, these eﬀects are only speculative but will
be addressed in further animal experiments.Acknowledgments: We thank F. K. Solem, I. Lauritsch and A. Fisch-
bach for excellent technical assistance.References
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